ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

remdesivir

Also written as “Remdesivir”, “Remdesivir (RDV)” and “RDV”.

Its studies are mostly in COVID-19, led by 4 companies.

Drug pageRemdesivir: every studyAll 48 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Feb 28, 20209 company-led studies, 1 open or runningNext primary completion: Sep 28, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences60 open or runningphase 3since Feb 28, 2020Feb 28, 2020none ahead
Biomed Industriesits history only10 open or runningphase 1since Jul 13, 2020Jul 13, 2020none ahead
Dr. Md. Alimur Rezaits history only10 open or runningphase 2since Oct 20, 2020Oct 20, 2020none ahead
Pfizerits history only11 open or runningphase 3since May 5, 2025May 5, 2025Sep 28, 2027phase 3 · NCT07013474

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Gilead Sciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2016Named remdesivirINNProposed as its International Nonproprietary Name in WHO's List 116
  2. Feb 28, 2020First studies: 2 phase 3 studies in COVID-19First studyNCT04292899, NCT04292730
  3. Jun 8, 2020Phase 3 study in COVID-19NCT04431453 · 59 enrolled · United States, Italy, Spain and more
  4. Aug 5, 2020Phase 3 study in COVID-19NCT04501952 · 584 enrolled · United States, Denmark, Spain and more
  5. Aug 26, 2020Phase 2 study in COVID-19NCT04539262 · 156 enrolled · United States
  6. Feb 8, 2021Phase 3 study in COVID-19NCT04745351 · 249 enrolled · United States, Brazil, Portugal and more

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“RNA-directed RNA polymerase L inhibitor; Replicase polyprotein 1ab inhibitor”ChEMBL 37, by rule

Studies

All 6 Gilead Sciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04745351COVID-19 · United States, Brazil, Portugal and more3TerminatedApr 20, 2022249
NCT04539262COVID-19 · United States2CompletedFeb 26, 2021156
NCT04501952COVID-19 · United States, Denmark, Spain and more3TerminatedMay 6, 2021584
NCT04431453COVID-19 · United States, Italy, Spain and more3CompletedFeb 10, 202359
NCT04292899COVID-19 · United States, China, France and more3CompletedApr 9, 20204,891
NCT04292730COVID-19 · United States, China, France and more3CompletedApr 29, 20201,113

How it is read

Names in the registry

  • “Remdesivir”, 5 entries
  • “remdesivir”, 1 entry
  • “Remdesivir (RDV)”, 1 entry
  • “RDV”, 1 entry
  • “Drug: GS-5734 - 1.00 mg/kg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.